Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
14.60
+0.72 (5.19%)
Dec 20, 2024, 4:00 PM EST - Market closed
Inhibrx Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | 1,728 | -154.96 | -115.33 |
| Depreciation & Amortization | 1.89 | 1.19 | 1.23 |
| Loss (Gain) From Sale of Assets | 0.01 | 0 | 0.02 |
| Loss (Gain) on Equity Investments | 1.63 | 1.63 | - |
| Stock-Based Compensation | 57.81 | 20.69 | 17.79 |
| Other Operating Activities | -1,999 | 0.13 | 1.62 |
| Change in Accounts Receivable | -0.12 | -0.54 | 0.13 |
| Change in Accounts Payable | 25.27 | 3.45 | -0.38 |
| Change in Unearned Revenue | 0.17 | - | -1.1 |
| Change in Other Net Operating Assets | 42.05 | -0.61 | 5.21 |
| Operating Cash Flow | -143.21 | -129.01 | -90.81 |
| Capital Expenditures | -6.02 | -4.59 | -0.69 |
| Investing Cash Flow | -6.02 | -4.59 | -0.69 |
| Other Financing Activities | 133.73 | 133.6 | 91.5 |
| Financing Cash Flow | 4.18 | 133.6 | 91.5 |
| Free Cash Flow | -149.23 | -133.6 | -91.5 |
| Free Cash Flow Margin | -9517.28% | -8176.25% | -6957.95% |
| Cash Income Tax Paid | 0 | 0 | 0 |
| Levered Free Cash Flow | - | -73.49 | - |
| Unlevered Free Cash Flow | - | -73.49 | - |
| Change in Net Working Capital | - | -4.69 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.